glp-1 care credit Weight Loss- Compounded Semaglutide – Lolachi Institute GLP-1Care Vanilla Pudding Shake

In accordance with Dong et al

Who Might Benefit Zepbound may be the strongest option for Hashimoto's patients who: Have a BMI of 30 or greater, or 27 or greater with at least one weight-related condition Haven't achieved meaningful weight loss with other medications or lifestyle interventions Have significant insulin resistance or prediabetes alongside their Hashimoto's Carry improved inflammatory markers (hsCRP above 3.0 mg/L) Want the maximum weight loss potential currently available in a single medication Don't have a history of medullary thyroid cancer or MEN2 Zepbound is FDA-approved for chronic weight management, so Hashimoto's patients who meet the BMI criteria have a recognized pathway to treatment

doi: 10.1111/j.1365-2788.2005.00641.x 51 BertellaLMoriIGrugniGPignattiRCerianiFMolinariEet al

PSG estimates that over 5% of the Medicare Part D population is already taking a GLP-1 for diabetes in 2024, and this number could easily double in the coming years